HISTORICAL FACTS: Eli lilly - Caught on Camera

Dear Eli Lilly Stock Fans, Mark October 29 on Your Calendar

Eli Lilly’s weight-loss boom faces fierce competition, but its next earnings report could reveal why the best may still be ahead.

Barchart · Oct 26

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

MarketBeat · Oct 26

Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

MarketBeat · Oct 21

US stocks: Dow, S&P 500 end higher as traders shift from AI to healthcare

After a rocky start, the S&P 500 experienced a resurgence, largely spurred by investments in the healthcare and consumer segments. Investors seemed to distance themselves from technology stocks, anxious about mounting debts in the AI sector. Eli Lilly and UnitedHealth rose thanks to favorable evaluations from Deutsche Bank, whereas Broadcom…

The Economic Times · Oct 15

GLP-1 Drugs Now Start as Low as $149 — But There’s a Catch

For Americans who have been priced out of popular weight-loss medications, a $149 monthly price tag sounds like welcome news. After years of seeing drugs...

Saving Advice · Oct 14

Eli Lilly and Company Earnings Preview: What to Expect

Eli Lilly and Company is set to report its Q3 results soon, with analysts anticipating single-digit EPS growth alongside continued earnings growth.

Barchart · Oct 14

Poison Center Exposures to Bootleg Retatrutide Nearly Double in Three Months as FDA Logs Two Death Reports

Poison centers logged 862 retatrutide exposures in three months, as the FDA received two death reports. Whether the drug caused the deaths is not established.

Medical Daily · Oct 14

How to Play TRXB Stock After the TRex Bio IPO

TRex Bio has Eli Lilly’s backing, but its IPO didn't really impress Wall Street. Is this biotech newcomer worth a shot, or should investors let the dust settle first?

Barchart · Oct 13

How ‘people power’ and business transformed medicine, but created a whole new set of risks

There’s been a shift in how some medicines and therapeutic products are accessed and used.

The Conversation · Oct 11

Ozempic and Zepbound Makers Report Slower Aging Clocks, but Unreviewed Data Do Not Prove Patients Age Slower

Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know.

Medical Daily · Oct 8